Literature DB >> 15803050

Zymosan-induced generalized inflammation: experimental studies into mechanisms leading to multiple organ dysfunction syndrome.

Thomas J H Volman1, Thijs Hendriks, R Jan A Goris.   

Abstract

Patients suffering from multiple organ dysfunction syndrome (MODS) comprise a heterogeneous population, which complicates research in its pathogenesis. Elucidation of the mechanisms involved in the development of MODS will ultimately necessitate the collection of tissue samples and the performance of invasive procedures. These requirements greatly reduce the possibilities for research in human subjects. Therefore, an animal model for MODS is a necessary and valuable tool. In the mid 1980s, the zymosan-induced generalized inflammation (ZIGI) model was introduced. Intraperitoneal injection of zymosan in mice or rats leads, in the course of 1 to 2 weeks, to increasing organ damage and dysfunction. The ZIGI model has been recognized as the one that best resembles human MODS and it has been used widely to study systemic inflammation in relation to organ failure. This review describes the ZIGI model and gives an overview of the results obtained.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15803050     DOI: 10.1097/01.shk.0000155350.95435.28

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  41 in total

1.  Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation.

Authors:  Hongkuan Fan; Donald Wong; Sarah H Ashton; Keith T Borg; Perry V Halushka; James A Cook
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

2.  Melanocortins protect against multiple organ dysfunction syndrome in mice.

Authors:  Alessandra Bitto; Francesca Polito; Domenica Altavilla; Natasha Irrera; Daniela Giuliani; Alessandra Ottani; Letteria Minutoli; Luca Spaccapelo; Maria Galantucci; Renzo Lodi; Giuseppe Guzzo; Salvatore Guarini; Francesco Squadrito
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 3.  Murine Models of Sepsis and Trauma: Can We Bridge the Gap?

Authors:  Julie A Stortz; Steven L Raymond; Juan C Mira; Lyle L Moldawer; Alicia M Mohr; Philip A Efron
Journal:  ILAR J       Date:  2017-07-01

4.  PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes.

Authors:  Qian Liu; Yi Lv; Min Zhao; Yiduo Jin; Jiangyang Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

5.  Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival.

Authors:  Iglika Djoumerska-Alexieva; Lubka T Roumenina; Tsvetanka Stefanova; Tchavdar Vassilev; Jordan D Dimitrov
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

6.  Evodiamine Inhibits Zymosan-Induced Inflammation In Vitro and In Vivo: Inactivation of NF-κB by Inhibiting IκBα Phosphorylation.

Authors:  Xia Fan; Jun-Yu Zhu; Yu Sun; Li Luo; Jun Yan; Xue Yang; Jing Yu; Wan-Qi Tang; Wei Ma; Hua-Ping Liang
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

7.  Prostaglandins mediate zymosan-induced sickness behavior in mice.

Authors:  Juliana B M Lima; Clarice C Veloso; Fabiana C Vilela; Alexandre Giusti-Paiva
Journal:  J Physiol Sci       Date:  2016-10-03       Impact factor: 2.781

8.  N-acetylcysteine administration is associated with reduced activation of NF-kB and preserves lung dendritic cells function in a zymosan-induced generalized inflammation model.

Authors:  Hong-Wei Wang; Wen Yang; Jiang-Yang Lu; Fei Li; Jun-Zhong Sun; Wen Zhang; Nan-Nan Guo; Lei Gao; Jia-Rui Kang
Journal:  J Clin Immunol       Date:  2012-12-16       Impact factor: 8.317

9.  Role of PPAR-delta in the development of zymosan-induced multiple organ failure: an experiment mice study.

Authors:  Maria Galuppo; Rosanna Di Paola; Emanuela Mazzon; Tiziana Genovese; Concetta Crisafulli; Irene Paterniti; Elisabetta Cuzzocrea; Placido Bramanti; Amar Kapoor; Christoph Thiemermann; Salvatore Cuzzocrea
Journal:  J Inflamm (Lond)       Date:  2010-02-18       Impact factor: 4.981

10.  Inhibition of zymosan-induced kidney dysfunction by tyrphostin AG-490.

Authors:  Petya Dimitrova; Valeriya Gyurkovska; Irina Shalova; Luciano Saso; Nina Ivanovska
Journal:  J Inflamm (Lond)       Date:  2009-05-05       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.